In clinical studies, nasal delivery devices can include: nose droppers, sprays, needleless syringes, breath-powered bi-directional nasal devices, pressurized meter dose inhalers, and pressurized olfactory delivery [8,9,18]
Starting at a lower dose allows tissues to respond without overstimulation, then the higher dose in Phase 2 extends and deepens that response
Case reports and small open-label use in clinics pop up online, but without standardized outcome measures, no control groups, and no objective biomarkers
Visit goal.md for details.
However, regenerative and age-related benefits typically require a longer duration and may emerge progressively over several weeks or months, depending on the individuals baseline condition and treatment protocol